- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00217919
Reducing Risk Factors in Peripheral Arterial Disease
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
BACKGROUND:
Patients with PAD have a 3- to 4-fold higher risk of cardiovascular morbidity and mortality compared to patients without PAD. Risk of future cardiovascular events is comparable between patients with PAD and coronary artery disease (CAD). While improved atherosclerotic risk factor treatment has reduced cardiovascular morbidity and mortality in patients with CAD, such treatment in patients with PAD remains suboptimal. Intensity of cholesterol-lowering therapy, specifically, is significantly poorer in patients with PAD as compared to CAD. Data show that fully 69 percent of patients with PAD from a non-invasive vascular laboratory in Chicago did not have the recommended LDL-C level of less than 100 mg/dl. Our data from a national survey indicate that physicians believe atherosclerotic risk factor treatment is less important for patients with PAD than for patients with CAD. Our data also show that many patients with PAD are unaware of their increased risk of cardiovascular events and under-appreciate the importance of risk factor treatment in PAD. These findings likely contribute to risk factor under-treatment in patients with PAD. Clinical trials such as this are needed to demonstrate whether PAD risk factors can be reduced. If effective, this clinical trial will also encourage clinicians to adopt the proven intervention to lower cardiovascular risks in patients with PAD
DESIGN NARRATIVE:
This randomized, controlled clinical trial will test the ability of a health-counselor mediated telephone counseling intervention as compared to usual care to reduce LDL-C levels in patients with PAD. The study involves patients with PAD who have LDL-C levels greater than 100 mg/dl at baseline identified from non-invasive vascular laboratories in Chicago, IL and Worcester, MA. For their primary specific aim, the investigators hypothesize that subjects randomized to the intervention condition will achieve a reduction in LDL-C of at least 11.1 mg/dl greater than the reduction in LDL-C for subjects randomized to the usual care condition at 12-month follow-up. In their secondary aim, they will determine whether the telephone counseling intervention increases the proportion of PAD patients with LDL-C less than 100 mg/dl as compared to the usual care condition at 12-month follow-up. To identify the mediators of the intervention, in their exploratory aims they will determine whether patients in the intervention condition achieve greater increases (improvement) in specific behavioral and knowledge and attitude mediators that will be targeted by the intervention, as compared to patients in the usual care condition.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60611
- Northwestern University, Feinberg School of Medicine
-
-
Massachusetts
-
Worcester, Massachusetts, Соединенные Штаты, 01655
- University of Massachusetts Medical School
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Life expectancy greater than 1 year
- Has a telephone
- English-speaking
- Willing to use acceptable methods of contraception
- Have a primary care physician
Exclusion Criteria:
- Currently undergoing cancer treatment or plans to begin treatment
- Psychiatric illness or cognitive impairment
- Intolerance to two or more cholesterol-lowering drugs
- Plans to move out of the area within one year of study entry
- Wheel-chair bound or unable to walk outside of home
- Below- or above-knee amputation
- Unstable angina
- Current foot ulcers
- LDL-C less than 70 mg/dl at baseline
- Debilitating chronic obstructive lung disease
- Major surgery within 3 months prior to study entry or plans to undergo major surgery within 1 year of study entry
- Current participation in another clinical trial. A six month period will be required after completing another clinical trial before an individual can become eligible for the current trial.
- Ischemic rest pain
- Pregnancy or plan to become pregnant
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Без вмешательства: 2
Обычный уход
|
|
Экспериментальный: 1
Health-Counselor Mediated Telephone Counseling Intervention
|
A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study. We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Временное ограничение |
---|---|
LDL-C levels
Временное ограничение: Measured at baseline and Month 12
|
Measured at baseline and Month 12
|
LDL-C lowering knowledge, attitude, and behavior
Временное ограничение: Measured at baseline and Month 12
|
Measured at baseline and Month 12
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Mary McDermott, MD, Northwestern University
Публикации и полезные ссылки
Общие публикации
- Pagoto SL, McDermott MM, Reed G, Greenland P, Mazor KM, Ockene JK, Whited M, Schneider K, Appelhans B, Leung K, Merriam P, Ockene I. Can attention control conditions have detrimental effects on behavioral medicine randomized trials? Psychosom Med. 2013 Feb;75(2):137-43. doi: 10.1097/PSY.0b013e3182765dd2. Epub 2012 Nov 28.
- McDermott MM, Greenland P, Reed G, Mazor KM, Merriam PA, Graff R, Tao H, Pagoto S, Manheim L, Kibbe MR, Ockene IS. Gender differences in cholesterol-lowering medication prescribing in peripheral artery disease. Vasc Med. 2011 Dec;16(6):428-35. doi: 10.1177/1358863X11425879.
- McDermott MM, Reed G, Greenland P, Mazor KM, Pagoto S, Ockene JK, Graff R, Merriam PA, Leung K, Manheim L, Kibbe MR, Olendzki B, Pearce WH, Ockene IS. Activating peripheral arterial disease patients to reduce cholesterol: a randomized trial. Am J Med. 2011 Jun;124(6):557-65. doi: 10.1016/j.amjmed.2010.11.032.
- McDermott MM, Mazor KM, Reed G, Pagoto S, Graff R, Merriam P, Kibbe M, Greenland P, Ockene J, Olendzki B, Huimin Tao, Ockene I. Attitudes and behavior of peripheral arterial disease patients toward influencing their physician's prescription of cholesterol-lowering medication. Vasc Med. 2010 Apr;15(2):83-90. doi: 10.1177/1358863X09353653. Epub 2010 Jan 29.
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 296
- R01HL073912 (Грант/контракт NIH США)
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .